DMT-Nexus member
Posts: 2889 Joined: 31-Oct-2014 Last visit: 03-Nov-2018
|
The Colorado department of public health and environment awarded MAPS a $2 million grant for a MAPS planed study of marijuana for PTSD in 76 United states veterans, fully funding the planed study. www.MAPS.org should have more information on this topic. -EG
|
DMT-Nexus member
Posts: 2889 Joined: 31-Oct-2014 Last visit: 03-Nov-2018
|
http://www.maps.org/maps...s-release-maps-receives-$2-million-grant-from-colorado-for-study-of-medical-marijuana-for-ptsd
|
DMT-Nexus member
 
Posts: 3968 Joined: 21-Jul-2012 Last visit: 15-Feb-2024
|
You know, I'm pretty excited to be alive right now and to be witness to these massive policy changes underway. It's beautiful. Thanks, CO,thanks OR voters, thanks WA and even DC. And thank you, MAPS,ICEERS,and all you awesome nexians and nexiites for all your tireless freak flag waving.  Sine experientia nihil sufficienter sciri potest -Roger Bacon
*γνῶθι σεαυτόν*
|
DMT-Nexus member
Posts: 2889 Joined: 31-Oct-2014 Last visit: 03-Nov-2018
|
Here are some other recent MAPS activities in the state of Colorado: Quote:March 11, 2017 Dear friends and supporters, Our Phase 2 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) are continuing to wrap up, clearing the way for Phase 3 trials. On February 24, our second-largest trial of MDMA-assisted psychotherapy for PTSD was officially completed in Boulder, Colorado. We’re now preparing the protocol for our Phase 3 clinical trials—starting later this year—which will be the final stage of research needed to make MDMA a legal medicine.[ Www.maps.org/quote] Quote:On November 30, 2016, the FDA cleared the upcoming MAPS-sponsored Phase 1 study on the effect of MDMA on fear extinction learning in healthy volunteers. Principal Investigator Barbara Rothbaum, Ph.D., a leading PTSD researcher, will conduct the study at Emory University in Atlanta, Georgia. The original protocol was approved by the Institutional Review Board (IRB) on July 26, 2016. The DEA is currently reviewing the protocol, with the study expected to begin in 2017. http://www.maps.org/rese...mp;pk_kwd=training-intro Quote:MDMA-Assisted Psychotherapy for PTSD: Boulder, Colorado (Intern Study) The next phase (Phase 3) of our clinical development plan for MDMA-assisted psychotherapy for PTSD will require many more male/female co-therapist teams than are currently available. Finding a cost-effective and sustainable way to recruit effective therapists is therefore a top priority. In this pilot study, we are investigating the effectiveness of MDMA-assisted psychotherapy for PTSD when one member of the standard male/female co-therapist team is a healthcare intern (being trained in therapy, social work, or nursing). The other member of each team is a professional therapist trained in our treatment method. As interns work for free in exchange for fulfilling required training hours under professional supervision, this approach may help reduce costs and train the next generation of psychedelic therapists. Principal Investigator: Marcela Ot'alora, M.A., L.P.C. Co-Investigator: Jim Grigsby, Ph.D. Sub-Investigator/Study Physician: Will Van Derveer, M.D. Sub-Investigator: Alison McQueen, M.A., L.P.C. Sub-Investigator: Bruce Poulter, R.N., M.P.H. Sub-Investigator: Saj Razvi, M.A., L.P.C. Sub-Investigator: Sandra Van Derveer, M.A. Intern Investigator: Sara Giron, M.A. Location: Boulder, CO Subjects will be U.S. veterans with PTSD, mostly from Iraq, Afghanistan, or Vietnam, along with survivors of childhood sexual abuse, assault, rape, and others. This study has been cleared by the Food and Drug Administration and approved by the Drug Enforcement Administration and an Institutional Review Board. http://www.maps.org/mdma-boulder [quote]Therapist Training Study: 22nd and 23rd Participants Enrolled in Colorado Written on January 25, 2017. On January 11 and January 25, 2017, the 22nd and 23rd participants were enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. The new participants were enrolled at the Boulder, Colorado, study site led by Principal Investigator Marcela Ot'alora, M.A., L.P.C. Michael Mithoefer, M.D., and Ann Mithoefer, B.S.N., are serving as Principal Investigators at the site in Charleston, South Carolina. Enrollment in this study is limited by invitation only to therapists in training to work on MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD. This study has currently enrolled 23 out of 100 participants across the study sites in Colorado and South Carolina http://www.maps.org/rese...mp;pk_kwd=training-intro -eg
|
DMT-Nexus member
Posts: 2889 Joined: 31-Oct-2014 Last visit: 03-Nov-2018
|
The other day an individual expressed to me that he did not believe that MAPS or MAPS researchers were located in the state of colorado, when in fact nothing could be further from the truth. ....MAPS revived a $2 million grant from the state of colorado for cannabis research, and is facilitating a large MDMA research project centered in boulder, colorado, they also.accept research from many independent contributors located in the state of Colorado. MAPS is world-wide, and contributors to MAPS are scattered across the United states and the globe. MAPS has even published unsanctioned research such as Casey hardison's 2C-t-7 research: Quote:Casey Hardison, a graduate student at the University of Idaho, conducted an informal survey of 2C-T-7 users at the Entheobotany conference in Palenque, Mexico in February 2000. Noticing that quite a few people were conducting bioassays of the material, Hardison seized the opportunity to perform some informal impromptu research. He designed a survey which was handed out to conference attendees, and received 48 responses. The results of this survey were published in the Summer 2000 issue of the MAPS Bulletin under the title "An Amateur Qualitative Study of 48 2C-T-7 Subjective Bioassays." https://erowid.org/chemi.../article1/hardison.shtml Researchers from all over the globe, from many backgrounds and fields, working for many different facilities and organizations contribute to MAPS, many MAPS researchers are located in Colorado, further more, MAPS sanctioned and funded research is occurring in Colorado, specifically regarding cannabis and MDMA. Colorado is a rich state for psychedelic research, from MAPS work, to student groups like "Naropa Alliance for Psychedelic Studies", to chemists and pharmacologists running independent research and then contributing to various psychedelic research outlets like MAPS or heffter. -eg
|